Aethlon Medical Announces Significant Viral Load Reduction In Landmark Medical Device Study To Treat HIV/AIDS

Aethlon Medical, Inc. (OTCBB:AEMD) announced results of the “first-in-man” study of the Aethlon Hemopurifier® to treat Human Immunodeficiency Virus (HIV), the disease that causes Acquired Immune Deficiency Syndrome (AIDS). In the study, viral load was reduced by 92% in an HIV-infected individual who received a total of twelve Hemopurifier® treatments administered thrice weekly over the span of one month.

More: continued here

Filed under: HIV / AIDS on March 13th, 2009